Nordhealth AS · OSL:NORDH
Nordhealth AS — Q3 2026 Earnings Presentation
46 slides from Nordhealth AS's earnings presentation, Nov 10, 2026
Slide 1: Nordhealth
(X] nordhealth
Slide 2: Q3 2026 presentation
Q3 2026 presentation 10 November 2026
Slide 3: Today's presenters
Todayʼs presenters Charles MacBain Alexander Cram CEO CFO Nordhealth 3
Slide 4: Agenda
Agenda 1.0 Company Update 2.0 Veterinary BU Update 3.0 Therapy BU Update 4.0 Financial Results 5.0 Guidance 6.0 Q&A Nordhealth 4
Slide 5: Company Update
01 Company Update Charles MacBain, CEO Nordhealth 5
Slide 6: 2026 Objectives to unlock profitable growth
2026 Objectives to unlock profitable growth 1. Build world leading AIPMS across Therapy & Veterinary 2. Radically reduce time to value from signed to onboarded, especially for enterprise 3. Localise Provet for Germany 4. Complete majority migration of Therapy Aspit Desktop users to Unified Platform
Slide 7: 43% organic and acquisition-led growth CAGR since 2018
43% organic and acquisition-led growth CAGR since 2018 Signed ARR M€ R 43% CAG Reported in constant currency (using 2025 year end currency rates). Nordhealth 7
Slide 8: 13.5% YoY ARR Growth
13.5% YoY ARR Growth ARR M€ ● 13.5% YoY ARR growth ● 108.8% Net retention rate primarily driven by Provet expansion within enterprise clients ● Low 3.2% churn rate Reported in constant currency (using 2025 year end currency rates). Nordhealth 8
Slide 9: Veterinary Update
02 Veterinary Update Charles MacBain, CEO Nordhealth 9
Slide 10: Veterinary business update
Veterinary business update Missions 1. Continued expansion in UK, US and Germany ○ Signed €394k new ARR Q3 ○ Mo Backer started as VP of marketing ○ Over 100 Vets4Pets clinics live at the end of Q3 ○ In total, there are now over 3,000 clinics live on our flagship platform, Provet 2. Build leading AI
Slide 11: 14.4% YoY Veterinary ARR growth
14.4% YoY Veterinary ARR growth ARR M€ ● ARR grew 14.4% YoY, an increase compared to Q2 2026 YoY, due to UK enterprise roll-out. ● Net retention rate 110.6%, primarily driven by enterprise clients rolling out new clinics ● Churn was 2.6% Reported in constant currency (using 2025 year end currency
Slide 12: YTD Veterinary adj. EBITDA - CAPEX
YTD Veterinary adj. EBITDA CAPEX Main drivers of Adj. EBITDACAPEX €0.8M change YTD Q3 2026 vs YTD Q3 2025 ● Gross profit €0.7M ● Product development €0.4M ● Professional services €0.7M ● Sales & Marketing €0.6M ● General & Administrative €0.6M Key drivers of changes in EBITDA C
Slide 13: US, UK, Southern Europe propelling growth
US, UK, Southern Europe propelling growth ARR M€ ● 52% of ARR at the end of September 2026 came from outside Nordics vs. 23% at the end of 2022 ● Large opportunity to localise Provet in DACH Reported in constant currency (using 2025 year end currency rates). Nordhealth 13
Slide 14: Provet's enterprise solution is well positioned to capture enterprise opportunity
Provetʼs enterprise solution is well positioned to capture enterprise opportunity ARR M€ • Enterprise share of total ARR has grown from 29% in 2022 to 44% in Q3 2026 • 56% of ARR growth since 2022 has come from enterprise clients • Despite focus on enterprise, our customer concentration remains lo
Slide 15: Veterinary Migration to Provet Progressing
Veterinary Migration to Provet Progressing ARR M€ ● Cloud share of ARR increased from 43% in 2022 to 90% in Q3 2026. ● Vetserve and Provet Win were sunset in 2024, Provet Net in 2025 and Sanimalis in 2026. ● We are working on finalizing VetVision Denmark) migration, and investing in Provet locali
Slide 16: Therapy Update
03 Therapy Update Charles MacBain, CEO Nordhealth 16
Slide 17: Therapy business update
Therapy business update Missions 1. Build leading AI PMS ○ In Q3 alone, we delivered over 100,000 hours of transcription and over 200,000 AI-generated notes. ○ AI improvements: including AI-personalised templates and an AI engine upgrade. 2. Aspit migration ○ 1,642 users migrated at end of Q3, up fr
Slide 18: 12.1% YoY Therapy ARR growth
12.1% YoY Therapy ARR growth ● ARR growth at 12.1% YoY, driven by sales initiatives ● Net retention rate 105.8%, boosted by AI scribe ● Gross churn reduced to 4.2% Reported in constant currency (using 2025 year end currency rates). Nordhealth 18
Slide 19: YTD Therapy adj. EBITDA - CAPEX
YTD Therapy adj. EBITDA CAPEX Main drivers of Adj. EBITDACAPEX change YTD Q3 2026 vs YTD Q3 2025 ● Gross profit €1.1M ● Sales & Marketing €0.4M Key drivers of changes in EBITDA CAPEX are increase in recurring revenue and investments made for marketing initiatives. Excludes group allocati
Slide 20: Continued growth in Cloud PMS
Continued growth in Cloud PMS ARR M€ ● Cloud share of ARR increased from 46% in 2022 to 61% in Q3 2026 ● Q3 increase in ARR of Cloud comes from accelerated pace of migration Reported in constant currency (using 2025 year end currency rates). Nordhealth 20
Slide 21: Financial Results
04 Financial Results Alexander Cram, CFO Nordhealth 21
Slide 22: 17.0% growth in total quarterly reported recurring revenues YoY
17.0% growth in total quarterly reported recurring revenues YoY €ʼM • Total reported revenues grew by 17.5% YoY to €15.2M in Q3/26 €12.9M in Q3/25 • Reported recurring revenues grew by 17.0% YoY to €13.5M in Q3/26 €11.5M in Q3/25 • Share of recurring revenue in Q3/26 was 88.6% 89.0% in Q3/25
Slide 23: 14.3% growth in total YTD Q3 reported recurring revenues YoY
14.3% growth in total YTD Q3 reported recurring revenues YoY €ʼM • Total reported revenues grew by 11.9% YoY to €42.8M in Q3 YTD 2026 €38.3M in Q3 YTD 2025 • Reported recurring revenues grew by 14.3% YoY to €38.7M in Q3 YTD 2026 €33.8M in Q3 YTD 2025 • Share of recurring revenue in Q3 YTD 2026
Slide 24: Quarterly adj. EBITDA - CAPEX
Quarterly adj. EBITDA CAPEX Adj. EBITDACAPEX improved €1.5M Q3/26 vs Q3/25 • Gross Profit €0.7M • General & Administrative €0.6M • Professional Services €0.2M • Product development €0.4M Key drivers of changes in EBITDA CAPEX are increase in paid development and recurring revenue.
Slide 25: YTD Q3 adj. EBITDA - CAPEX
YTD Q3 adj. EBITDA CAPEX Adj. EBITDACAPEX improved €1.1M YTD Q3/26 vs YTD Q3/25 • Gross Profit €1.7M • General & Administrative €0.5M • Professional Services €0.9M • Product development €0.3M • Sales and marketing €0.1M Key drivers of changes in EBITDA CAPEX are increase in recu
Slide 26: Q3 YTD adjusted cash flow improved YoY
Q3 YTD adjusted cash flow improved YoY €ʼM Adjusted cash flow improved by €0.9M, from €1.6M in Q3 YTD 2025 to €0.7M in Q3 YTD 2026, primarily due to improving adjusted operating cash flow, linked to improved Adjusted EBITDA CAPEX. Nordhealth 26
Slide 27: Strong cash position and no debt
Strong cash position and no debt Balance sheet 30 September 2026 €ʼM Assets • Cash, cash equivalents and money market funds amounted to EUR 11.6M at the end of Q3/26 vs EUR 16.5M at the end of Q3/25 • Intangible assets primarily consist of capitalised R&D expenses. Liabilities and equity • No inte
Slide 28: Guidance
05 Guidance Alexander Cram, CFO Nordhealth 28
Slide 29: Guidance update
Guidance update Expecting to perform well against 2026 Guidance ● Recurring Revenue ○ Guidance: Full year total reported recurring revenue of between €50M and €53M excluding acquisitions. ○ YTD Q3 2026 actual: €38.7M Full year 2026 €52.2M if continuing on Q3 run-rate). ○ Full year 2025 actual: €45
Slide 30: Financial calendar
Financial calendar Q4 2026 results presentation on 2 March 2027. Note: Nordhealth is currently undertaking an accounting standards conversion from Norwegian GAAP (current) to IFRS. For Full Year 2026 we plan to release our results in both NGAAP and IFRS. From 2027 onwards we will present results un
Slide 31: Q&A
06 Q&A Nordhealth 31
Slide 32: Appendix
(X) nordhealth Appendix ay
Slide 33: Key definitions - 1/2
Key definitions - 1/2 Recurring revenue includes revenues from software subscriptions as well as revenues from volume-based transactions (e.g., SMS messages) as well as rebates from third parties (e.g. payment solution providers). ARR is recurring revenue annualised by multiplying the quarter’s last
Slide 34: Key definitions - 2/2
Key definitions - 2/2 Adjusted cash flow is the sum of cash flow from operations and cash paid for capitalised expenses, adjusted for one-time expenses not likely to incur in the near future. Margins are used to compare relative profit between periods. EBITDA margin and EBITDA - CAPEX margin are cal
Slide 35: Profit & Loss statement
Profit & Loss statement Consolidated Income Statement Unaudited Unaudited Unaudited Unaudited Audited EUR in thousands Q3 2026 Q3 2025 YTD Q3 2026 YTD Q3 2025 FY 2025 Recurring revenue 13 457 11 505 38 697 33 843 45 647 Other revenue 1 737 1 422 4 143 4 427 5 194 Total revenue 15 195 12 927 42 840 3
Slide 36: Balance Sheet
Balance Sheet Consolidated Balance Sheet Unaudited Unaudited Audited EUR in thousands 30Sep-26 30Sep-25 31Dec-25 Intangible assets 12 712 13 238 13 226 Deferred tax assets 97 101 90 Other capitalized long-term expenses 145 216 198 Goodwill 32 104 36 573 35 004 Machinery and Equipment 242 277 272
Slide 37: Cashflow
Cashflow Consolidated Cash Flow Statement Unaudited Unaudited Unaudited Unaudited Audited EUR in thousands Q3 2026 Q3 2025 YTD Q3 2026 YTD Q3 2025 FY 2025 Cash flow from operations Profit before income taxes 2 016 2 164 10 742 7 840 12 292 Taxes paid in the period 29 7 63 54 40 Other
Slide 38: Business Segments
Business Segments 🐶Veterinary Therapy Other Business Cloud Non-Cloud Cloud Non-Cloud Cloud Non-Cloud Products Provet Vetera DACH EasyPractice Physica Navisec Provet Pay Diarium Psykbase Booking Portal Share of ARR 56% 6% 22% 14% 2% 0% Nordhealth 38
Slide 39: Strong organic growth accelerated by acquisition and migration strategy
Strong organic growth accelerated by acquisition and migration strategy 9 acquisitions completed since 2005 Migrated Migrated Migrated Migrated Migrated 2005 2009 2019 2019 2019 Acquired Praktiikka Vetserve In Progress In Progress In Progress Flagship 2021 2021 2022 2022…
Slide 40: Group - QoQ ARR growth
Group - QoQ ARR growth ARR M€ Reported in constant currency (using 2025 year end currency rates). Nordhealth 40
Slide 41: Veterinary - QoQ ARR growth
Veterinary - QoQ ARR growth ARR M€ Reported in constant currency (using 2025 year end currency rates). Nordhealth 41
Slide 42: Therapy - QoQ ARR growth
Therapy - QoQ ARR growth ARR M€ Reported in constant currency (using 2025 year end currency rates). Nordhealth 42
Slide 43: Group LTV / CAC continues to demonstrate strong unit economics
Group LTV / CAC continues to demonstrate strong unit economics 2022 2023 2024 2025 LTM Q3 2026 Average Implemented ARR growth 14.7% 23.0% 20.5% 8.7% 13.5% 16.1% New customer ARR 11.8% 9.4% 7.5% 4.0% 4.7% 7.5% Net upsell 6.3% 18.5% 18.1% 8.7% 12.0% 12.7% Churn rate -3.4% -4.9% -5.1% -4.0% -3.2% -4.1%
Slide 44: Veterinary long-term average churn less than 3%
Veterinary long-term average churn less than 3% 2022 2023 2024 2025 LTM Q3 2026 Average Implemented ARR growth 17.2% 42.9% 29.9% 10.9% 14.4% 23.0% New customer ARR 12.2% 9.7% 7.1% 3.4% 3.8% 7.2% Net upsell 7.1% 34.8% 27.6% 10.2% 13.2% 18.6% Churn rate -2.1% -1.6% -4.8% -2.7% -2.6% -2.8% Net retentio
Slide 45: Therapy long-term average churn at 5.6%
Therapy long-term average churn at 5.6% 2022 2023 2024 2025 LTM Q3 2026 Average Implemented ARR growth 13.9% 4.2% 9.2% 5.6% 12.1% 9.0% New customer ARR 11.3% 9.2% 8.1% 5.0% 6.4% 8.0% Net upsell 7.2% 3.2% 6.6% 6.5% 9.9% 6.7% Churn rate -4.6% -8.1% -5.4% -5.9% -4.2% -5.6% Net retention rate 102.6% 95.
Slide 46: Quarterly Headcount
Quarterly Headcount Keeping 2026 headcount stable to allow revenue growth to translate to increased EBITDA CAPEX 2025 13% YTD Q326 3% 2024 7% Nordhealth 46